AUG 8, 2026 · JOURNAL ARTICLE
Nuclear export inhibition activates TP53 pathways and is a potent therapeutic strategy in atypical teratoid rhabdoid tumors
Neuro-oncology Advances
Sound preclinical study with patient-derived models and in vivo validation showing XPO1 inhibition activates TP53 and reduces tumor burden, but lacks clinical trial data and human efficacy evidence.
Reported
Primary approachXPO1 inhibition via CRISPR knockdown and si…
Cell viability outcomeSignificant reduction in cell viability and…
Apoptosis outcomeIncreased apoptosis observed with selinexor…